Claims

1. A compound according to formula (I)



(I)

wherein:

n is 0, 1, 2 or 3;

R^1 is selected from

a. an optionally substituted straight chain or branched chain C_{1-6} alkyl group,

b. an optionally substituted straight chain or branched chain C_{2-6} alkenyl group,

c. an optionally substituted straight chain or branched chain C_{2-6} alkynyl group,

d. Aryl,

e. Aromatic heterocycle,

f. Heterocycle, and

g. hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected from: C_{3-7} cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR^{10}, $NR^{10}R^{11}$, $S(O)_pR^{10}$, $OC(O)R^{11}$, CO_2R^{10}, $CONR^{10}R^{11}$, $SO_2NR^{10}R^{11}$, halo and $NHSO_2R^{10}$, and where p is 0, 1 or 2;

R^2, R^3, R^4, R^6, R^7 and R^9 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo;

R^5 and R^8 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo, or together are a C_{2-6} alkylene chain;

R^{10} and R^{11} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R^{12}, halo, OR^{13}, $NR^{13}R^{14}$, $NR^{13}CO_2R^{12}$, CO_2R^{13}, $NR^{13}SO_2R^{12}$, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $SO_2NR^{13}R^{14}$, $C(O)NR^{13}R^{14}$, C_{3-7} cycloakyl, $O(C_{3-7}$ cycloalkyl), R^{15} and OR^{15}, where R^{12} is straight chain or branched chain C_{1-6} alkyl, R^{13} and R^{14} are each independently selected

from hydrogen and straight chain or branched chain C_{1-6} alkyl, and R^{15} is phenyl optionally substituted by R^{12}, OR^{13}, halo or haloalkyl;

Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{12}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{14}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$,

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

2. A compound according to Claim 1 wherein the substitution pattern of the imidazole is as depicted in formula (ID^1)



(ID^1)

3. A compound according to Claim 1 wherein the stereochemistry is as depicted in formula (IA)



(IA)

4. A compound according to any preceding Claim wherein n is 0 or 1.

5. A compound according to Claim 4 wherein n is 0.

6. A compound according to any preceding Claim wherein R^1 is hydrogen, Aryl, C_{2-6} alkenyl or a C_{1-6} alkyl group optionally substituted by one or more groups selected from C_{3-7} cycloalkyl, Aryl, Aromatic heterocycle, OR^{10}, CO_2R^{10}, halo and $NHSO_2R^{10}$.

7. A compound according to Claim 6 wherein R^1 is hydrogen, Aryl or a C_{1-6} alkyl group optionally substituted by a group selected from cyclohexyl and Aryl R^1 is hydrogen, Aryl or C_{1-6} alkyl optionally substituted by cyclohexyl or Aryl.

8. A compound according to Claim 7 wherein R^1 is hydrogen or C_{1-3} alkyl.

9. A compound according to Claim 8 wherein R^1 is hydrogen.

10. A compound according to any preceding Claim wherein R^2 and R^3 are each independently hydrogen or C_{1-6} alkyl.

11. A compound according to Claim 10 wherein R^2 and R^3 are both hydrogen.

12. A compound according to any preceding Claim wherein R^4 is hydrogen or C_{1-6} alkyl.

13. A compound according to Claim 12 wherein R^4 is hydrogen.

14. A compound according to any preceding Claim wherein R^6, R^7 and R^9 are each independently hydrogen or C_{1-3} alkyl.

15. A compound according to Claim 14 wherein R^6, R^7 and R^9 are each independently hydrogen or methyl.

16. A compound according to Claim 15 wherein R^6, R^7 and R^9 are all hydrogen.

17. A compound according to any preceding Claim wherein R^5 is hydrogen or C_{1-3} alkyl.

18. A compound according to Claim 17 wherein R^5 is hydrogen or methyl.

19. A compound according to Claim 18 wherein R^5 is methyl.

20. A compound according to any of Claims 17, 18 and 19 wherein R^8 is hydrogen or methyl.

21. A compound according to Claim 20 wherein R^8 is hydrogen.

22. A compound according to Claim 1, selected from:

(2*S*)-(-)-2-(2-aminoethoxy)-3-(1-phenyl-1*H*-imidazol-4-yl)propanoic acid;

(2*S*)-2-{[(1*R*)-2-amino-1-methylethyl]oxy}-3-[1-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]-propanoic acid;

(2*S*)-2-{[(1*R*)-2-amino-1-methylethyl]oxy}-3-(1-phenyl-1*H*-imidazol-4-yl)propanoic acid;

(2*S*)-2-{[(2*S*)-2-aminopropyl]oxy}-3-[1-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]propanoic acid;

(2*S*)-2-(2-aminoethoxy)-3-(1*H*-imidazol-4-yl)propanoic acid;

(2*S*)-2-{[(1*R*)-2-amino-1-methylethyl]oxy}-3-(1*H*-imidazol-4-yl)propanoic acid; and

(2*S*)-2-{[(1*R*)-2-amino-1-methylethyl]oxy}-3-[1-(2-pyridinyl)-1*H*-imidazol-4-yl]propanoic acid,

and pharmaceutically acceptable salts thereof.

23. A compound according to any of Claims 1 to 22 for use as a medicament.

24. A compound according to any of Claims 1 to 22 for use as a medicament for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

25. A pharmaceutical composition comprising a compound according to any of Claims 1 to 22 and a pharmaceutically acceptable carrier.

26. The use of a compound according to any of Claims 1 to 22 for the preparation of a medicament for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

27. A use according to Claim 26 wherein the medicament is for the treatment of a thrombotic condition.

28. A method of treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body, comprising administration of a compound according to any of Claims 1 to 22 to a subject in need of such treatment.

29. A process for the preparation of a compound according to formula (I)



(I)

wherein:

n is 0, 1, 2 or 3;

R^1 is selected from

a. an optionally substituted straight chain or branched chain C_{1-6} alkyl group,

b. an optionally substituted straight chain or branched chain C_{2-6} alkenyl group,

c. an optionally substituted straight chain or branched chain C_{2-6} alkynyl group,

d. Aryl,

e. Aromatic heterocycle,

f. Heterocycle, and

g. hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected from: C_{3-7} cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR^{10}, $NR^{10}R^{11}$, $S(O)_pR^{10}$, $OC(O)R^{11}$, CO_2R^{10}, $CONR^{10}R^{11}$, $SO_2NR^{10}R^{11}$, halo and $NHSO_2R^{10}$, and where p is 0, 1 or 2;

R^2, R^3, R^4, R^6, R^7 and R^9 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo;

R^5 and R^8 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo, or together are a C_{2-6} alkylene chain;

R^{10} and R^{11} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R^{12}, halo, OR^{13}, $NR^{13}R^{14}$, $NR^{13}CO_2R^{12}$, CO_2R^{13}, $NR^{13}SO_2R^{12}$, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $SO_2NR^{13}R^{14}$, $C(O)NR^{13}R^{14}$, C_{3-7} cycloakyl, $O(C_{3-7}$ cycloalkyl), R^{15} and OR^{15}, where R^{12} is straight chain or branched chain C_{1-6} alkyl, R^{13} and R^{14} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl, and R^{15} is phenyl optionally substituted by R^{12}, OR^{13}, halo or haloalkyl;

Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{12}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{14}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$,

or a tautomer thereof, comprising the steps of:

(i) preparing a compound according to formula (II)



(II)

wherein:

P^1 is an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{4-7} cycloalkyl group, an optionally substituted benzyl group or a tri(C_{1-6} alkyl)silyl group; and

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and n are as defined for formula (I); and

(ii) treating said compound of formula (II) with a reagent or combination of reagents suitable for removing the P^1 group.

30. A process for the preparation of a compound according to formula (I)



(I)

wherein:

n is 0, 1, 2 or 3;

R^1 is selected from

a. an optionally substituted straight chain or branched chain C_{1-6} alkyl group,

b. an optionally substituted straight chain or branched chain C_{2-6} alkenyl group,

c. an optionally substituted straight chain or branched chain C_{2-6} alkynyl group,

d. Aryl,

e. Aromatic heterocycle,

f. Heterocycle, and

g. hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected from: C_{3-7} cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR^{10}, $NR^{10}R^{11}$, $S(O)_pR^{10}$, $OC(O)R^{11}$, CO_2R^{10}, $CONR^{10}R^{11}$, $SO_2NR^{10}R^{11}$, halo and $NHSO_2R^{10}$, and where p is 0, 1 or 2;

R^2, R^3, R^4, R^6 and R^7 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo;

R^5 and R^8 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^{10} or halo, or together are a C_{2-6} alkylene chain;

R^9 is hydrogen;

R^{10} and R^{11} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R^{12}, halo, OR^{13}, $NR^{13}R^{14}$, $NR^{13}CO_2R^{12}$, CO_2R^{13}, $NR^{13}SO_2R^{12}$, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $SO_2NR^{13}R^{14}$, $C(O)NR^{13}R^{14}$, C_{3-7} cycloakyl, $O(C_{3-7}$ cycloalkyl), R^{15} and OR^{15}, where R^{12} is straight chain or branched chain C_{1-6} alkyl, R^{13} and R^{14} are each independently selected

from hydrogen and straight chain or branched chain C_{1-6} alkyl, and R^{15} is phenyl optionally substituted by R^{12}, OR^{13}, halo or haloalkyl;

Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{12}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{13}, $NR^{13}R^{14}$, CO_2R^{13}, $NR^{13}CO_2R^{14}$, R^{12}, halo, CN, haloalkyl, O(haloalkyl), SR^{13}, $S(O)R^{12}$, SO_2R^{12}, $OC(O)R^{13}$, $NR^{13}SO_2R^{12}$, $SO_2NR^{13}R^{14}$ and $C(O)NR^{13}R^{14}$,

or a tautomer thereof, comprising the steps of:

(i) preparing a compound according to formula (XIV)



(XIV)

wherein:

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8 and n are as defined for formula (I); and

(ii) treating said compound of formula (II) with a reagent or combination of reagents suitable for hydrolyzing the amide bond of the lactam ring.